Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years.

PubWeight™: 0.94‹?› | Rank: Top 15%

🔗 View Article (PMC 4316688)

Published in Cancer on June 10, 2014

Authors

Yuhree Kim1, Aslam Ejaz, Amit Tayal, Gaya Spolverato, John F P Bridges, Robert A Anders, Timothy M Pawlik

Author Affiliations

1: Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Articles cited by this

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78

Permutation tests for joinpoint regression with applications to cancer rates. Stat Med (2000) 24.62

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18

Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56

Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71

Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes (2001) 5.76

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64

Diabetes and cancer. Endocr Relat Cancer (2009) 5.04

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology (2010) 4.83

The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68

Epidemiology of hepatocellular carcinoma. Clin Liver Dis (2005) 4.29

Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82

Updated treatment approach to hepatocellular carcinoma. J Gastroenterol (2005) 3.43

A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13

Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12

The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis (2010) 2.96

Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med (2011) 2.94

Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89

Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci (2010) 2.86

Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology (2008) 2.66

Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology (2010) 2.30

Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer (2007) 2.23

Diabetes, prediabetes and cancer mortality. Diabetologia (2010) 2.22

Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) (2010) 2.19

Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09

3. Sampling variance of standardized mortality rates. Hum Biol (1966) 1.80

Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett (2008) 1.80

The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol (2010) 1.79

Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68

The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol (2009) 1.67

The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol (2009) 1.58

The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol (2008) 1.55

The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol (2008) 1.44

Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care (2012) 1.42

A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer (2009) 1.35

Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol (2007) 1.30

Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg (2003) 1.24

Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology (2008) 1.17

Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol (2011) 1.12

Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07

Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg (2013) 1.04

Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg (2013) 1.02

Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol (2013) 0.93

Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol (2012) 0.89

Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg (2013) 0.79

Articles by these authors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78

Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61

The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51

Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15

Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98

Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82

Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66

Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008. Patient (2010) 2.30

Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29

Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26

Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22

Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13

Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06

Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol (2007) 2.06

Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01

Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol (2008) 1.97

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94

Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94

Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg (2007) 1.87

Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg (2009) 1.85

Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) (2011) 1.82

The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82

Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer (2015) 1.82

Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79

Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One (2011) 1.79

Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78

A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg (2014) 1.76

Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71

Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg (2008) 1.69

Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg (2009) 1.68

Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. J Am Coll Surg (2009) 1.67

Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med (2004) 1.66

Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology (2013) 1.66

A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64

Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg (2012) 1.64

Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg (2011) 1.64

Sarcina organisms in the gastrointestinal tract: a clinicopathologic and molecular study. Am J Surg Pathol (2011) 1.61

Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol (2010) 1.60

Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg (2011) 1.59

Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59

Informed consent and the surgeon. J Am Coll Surg (2009) 1.58

The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58

Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (2014) 1.55

Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg (2012) 1.55

Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54

Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis. Ann Surg Oncol (2014) 1.53

Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53

The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg (2009) 1.52

Improving surgical outcomes through adoption of evidence-based process measures: intervention specific or associated with overall hospital quality? Surgery (2009) 1.51

Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2013) 1.50

Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol (2012) 1.50

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.50

Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg (2015) 1.46

Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 535 Patients. JAMA Surg (2015) 1.46

Assessing readmission after general, vascular, and thoracic surgery using ACS-NSQIP. Ann Surg (2013) 1.45

A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford) (2012) 1.45

ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford) (2009) 1.44

Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol (2009) 1.44

Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol (2012) 1.44

Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) (2011) 1.44

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer (2011) 1.43

Potential Economic Impact of Using a Restrictive Transfusion Trigger Among Patients Undergoing Major Abdominal Surgery. JAMA Surg (2015) 1.42

Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol (2009) 1.42

Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. World J Surg (2015) 1.42

Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surg (2016) 1.42

Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg (2009) 1.41

Trends in the quality of highly cited surgical research over the past 20 years. Ann Surg (2009) 1.41

Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg (2010) 1.37

National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg (2010) 1.36

Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol (2008) 1.35

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother (2015) 1.35

Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg (2010) 1.33

Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg (2008) 1.32

Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol (2011) 1.31

Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg (2008) 1.29

Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest (2004) 1.28

Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27

Overcoming bias in estimating the volume-outcome relationship. Health Serv Res (2006) 1.26

Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg (2007) 1.26

A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg (2012) 1.26

KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res (2009) 1.26

Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol (2011) 1.24

Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg (2008) 1.23

Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J Clin Invest (2008) 1.23

Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia. Hepatology (2011) 1.22

Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg (2008) 1.22